Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249418 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAACD274PDCD1 | |
| SCHEMBL20249108 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAALTA4HCNR2 | |
| SCHEMBL20249510 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAALTA4HCNR2 | |
| SCHEMBL20249506 | 0.92 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAALTA4HCNR2 | |
| SCHEMBL20249121 | 0.92 | ALDH1A1 (0.52) | ALDH1A1KDM4EGAACD274PDCD1 | |
| SCHEMBL20249107 | 0.89 | CCR9 (0.41) | CD274PDCD1LTA4HMEN1KMT2A | |
| SCHEMBL20249161 | 0.85 | HRH3 (0.45) | LTA4HKMT2AKCNH2GPR119 | |
| SCHEMBL20249155 | 0.82 | S1PR5 (0.54) | CD274PDCD1LTA4HKMT2A | |
| SCHEMBL20249249 | 0.82 | PPARD (0.43) | LTA4HKMT2AKCNH2GPR119 | |
| SCHEMBL20249125 | 0.81 | HRH3 (0.45) | LTA4HKMT2AKCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | ALDH1A1 944/4885KDM4E 470/4885GAA 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.